United States Neuromodulation Devices Market Outlook to 2033 - Implantable Neuromodulation Devices and Non-Invasive Neuromodulation Devices

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 What Is This Report About?
• 2.2 Neuromodulation Devices Market Segmentation
• 2.3 Definitions of Markets Covered in the Report

3 Neuromodulation Devices Market, United States

• 3.1 Neuromodulation Devices Market, United States, Revenue ($m), 2018-2033
  • 3.1.1 Implantable Neuromodulation Devices Market, United States, Revenue ($m), by Segment, 2018-2033
• 3.2 Neuromodulation Devices Market, United States, Volume (Units), 2018-2033
  • 3.2.1 Implantable Neuromodulation Devices Market, United States, Volume (Units), by Segment, 2018-2033
• 3.3 Neuromodulation Devices Market, United States, Average Price ($), 2018-2033
• 3.4 Neuromodulation Devices Market, United States, Company Share by Revenue ($m), 2025

4 Overview of Key Companies in United States, Neuromodulation Devices Market

• 4.1 Medtronic Plc
  • 4.1.1 Company Overview
• 4.2 Boston Scientific Corp
  • 4.2.1 Company Overview
• 4.3 Abbott Laboratories
  • 4.3.1 Company Overview
• 4.4 LivaNova Plc
  • 4.4.1 Company Overview
• 4.5 Nevro Corp
  • 4.5.1 Company Overview
• 4.6 Axonics Inc
  • 4.6.1 Company Overview
• 4.7 NeuroPace Inc
  • 4.7.1 Company Overview
• 4.8 Enterra Medical Inc
  • 4.8.1 Company Overview
• 4.9 B. Braun Melsungen AG
  • 4.9.1 Company Overview
• 4.10 Curonix LLC
  • 4.10.1 Company Overview
• 4.11 AirLife
  • 4.11.1 Company Overview
• 4.12 Bioness Inc
  • 4.12.1 Company Overview
• 4.13 Avanos Medical Inc
  • 4.13.1 Company Overview
• 4.14 Xavant Technology (Pty) Ltd
  • 4.14.1 Company Overview

5 Neuromodulation Devices Market Pipeline Products

6 Recent Developments

• 6.1 Corporate Communications
  • 6.1.1 Nov 25, 2025: SetPoint Medical to Present at Piper Sandler 37th Annual Healthcare Conference
  • 6.1.2 Nov 20, 2025: PhotoPharmics Exceeds Enrollment Goal with 350 Participants in Remote Phase 3 Clinical Trial for Parkinson's Disease
  • 6.1.3 Nov 18, 2025: NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD
  • 6.1.4 Nov 17, 2025: Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study
  • 6.1.5 Nov 17, 2025: MicroTransponder Appoints Dana G. Mead, Jr. as Chair and Cynthia Lucchese as Independent Director
  • 6.1.6 Nov 10, 2025: TEDCO Announces Recent Company Formation and Technology Assessment Awardees
  • 6.1.7 Nov 06, 2025: Synchron Secures $200 Million Series D Funding for Brain-Computer Interface Development
  • 6.1.8 Nov 06, 2025: PhotoPharmics Exceeds Enrollment Target with 350 Participants in Remote Clinical Trial
  • 6.1.9 Nov 05, 2025: Curonix Appoints Russell Fleeger as Chief Financial Officer
  • 6.1.10 Nov 04, 2025: BrainsWay Announces NIH Grant for Research on Accelerated Deep TMS for Alcohol Use Disorder
  • 6.1.11 Nov 03, 2025: Katrina Rouan Appointed Director of the Walter P. Reuther Library Archives of Labor and Urban Affairs
  • 6.1.12 Oct 30, 2025: End Brain Cancer Initiative Partners with Exvade Bioscience to Raise Awareness of Brain Cancer Study
  • 6.1.13 Oct 30, 2025: Siddiqui Performs World's First Robotic Microsurgical Intracranial Brain Surgery
  • 6.1.14 Oct 24, 2025: Payman Khales Becomes Integer President and CEO
  • 6.1.15 Oct 23, 2025: Miramont Wellness Centers Introduces New Device and Program for Treating Depression
  • 6.1.16 Oct 21, 2025: DCMH Welcomes Dr. Bryan Schatmeyer, Spine Surgeon
  • 6.1.17 Oct 21, 2025: Wayne State University Appoints New Director of the Institute of Gerontology
  • 6.1.18 Oct 20, 2025: Spark Biomedical Receives NIH Grant to Investigate tAN Technology for Alcohol Withdrawal Symptoms
  • 6.1.19 Oct 16, 2025: Wayne State Delegation Shares Expertise at National Science Foundation Workshop
  • 6.1.20 Oct 14, 2025: Zynex Appoints Bret Wise as Audit Committee Chair
  • 6.1.21 Oct 14, 2025: Jessica Rajko Appointed Acting Associate Dean of Academic and Faculty Affairs
  • 6.1.22 Oct 10, 2025: Nexalin Technology Attends the 2025 Maxim Growth Summit
  • 6.1.23 Oct 07, 2025: New Leadership Appointments Announced by Wayne State University's Vice President for Research & Innovation
  • 6.1.24 Oct 02, 2025: Wayne State University Collaboration With Applied Materials Supports Faculty Research And Career Pathways
  • 6.1.25 Oct 01, 2025: Cirtec Medical Appoints Steven Chevillotte To Board Of Directors
  • 6.1.26 Sep 25, 2025: Joe Hedges Appointed New Associate Director of David G. Pollart Center for Arts and Humanities
  • 6.1.27 Sep 24, 2025: Phase 3 Compass Pws Trial Of Intranasal Carbetocin Fails To Meet Primary Endpoint
  • 6.1.28 Sep 24, 2025: CWSL Alumna Sherry S. Bahrambeygui Elected to UC San Diego Foundation Board
  • 6.1.29 Sep 16, 2025: Cirtec Medical Welcomes Chris Cleary to its Board of Directors
  • 6.1.30 Sep 15, 2025: Inbrain Neuroelectronics Collaborates to Enhance Graphene-Based Brain-Computer Interfaces
  • 6.1.31 Sep 15, 2025: Kelly Young Appointed Interim Dean for College of Fine, Performing and Communication Arts
  • 6.1.32 Sep 08, 2025: UC San Diego Foundation Announces New Trustees
  • 6.1.33 Sep 05, 2025: Wayne State Anthropology Museum Receives $1.3 Million Bequest
  • 6.1.34 Aug 05, 2025: Avanos Medical Appoints Scott Galovan as CFO and David Pacitti to Board of Directors
  • 6.1.35 Jul 08, 2025: Medtronic Appoints Chad Spooner as Chief Financial Officer of MiniMed
  • 6.1.36 May 21, 2025: Medtronic Announces Leadership Change in Cardiovascular Portfolio
  • 6.1.37 Feb 13, 2025: Tim Ryan Elected to Battelle Board of Directors
• 6.2 Financial Announcements
  • 6.2.1 Jan 09, 2026: Sanuwave Health Reports Preliminary Q4 2025 Revenue of $13.3-$13.4 Million, Up 29-30% Year-Over-Year
  • 6.2.2 Nov 12, 2025: Solana Company to Release Third Quarter Operating Results
  • 6.2.3 Sep 25, 2025: Integer Announces Conference Call to Discuss Third Quarter 2025 Results
  • 6.2.4 Sep 02, 2025: Boston Scientific Announces 2025 Investor Day Meeting and Conference Call Discussing Third Quarter 2025 Results
  • 6.2.5 Jul 29, 2025: NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
  • 6.2.6 Jul 24, 2025: Avanos Medical to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
• 6.3 Government and Public Interest
  • 6.3.1 Nov 25, 2025: SetPoint Medical to Present at Piper Sandler 37th Annual Healthcare Conference
  • 6.3.2 Nov 03, 2025: Boston Scientific Announces Upcoming Investor Conference Schedule
  • 6.3.3 Oct 30, 2025: The Enrollment for Phase III Trial of the Company's Nivolumab Injection Has Been Completed in China
  • 6.3.4 Oct 27, 2025: Inspire Medical Systems, Inc. To Present At The 2025 UBS Global Healthcare Conference
  • 6.3.5 Oct 22, 2025: Vivani Medical to Present at ThinkEquity Conference
  • 6.3.6 Oct 10, 2025: Nexalin Technology Attends the 2025 Maxim Growth Summit
  • 6.3.7 Sep 30, 2025: Sequana Medical Features Alfapump System at 2025 Portal Intervention Symposium
  • 6.3.8 Sep 25, 2025: Integer Announces Conference Call to Discuss Third Quarter 2025 Results
  • 6.3.9 Sep 24, 2025: Vivani Medical To Present At The Emerging Growth Conference
  • 6.3.10 Sep 24, 2025: Eysz Announces Positive Results of NIH-Funded Study on Novel Absence Seizure Screening Tool
  • 6.3.11 Sep 02, 2025: Compelling Data at ESC Congress 2025 Reinforce Safety and Performance of the Medtronic Omniasecure Defibrillation Lead, Including in the Left Bundle Branch Area
  • 6.3.12 Aug 12, 2025: Integer to Present at 2025 Wells Fargo Healthcare Conference on Sept. 4
  • 6.3.13 Aug 04, 2025: Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
  • 6.3.14 Jul 22, 2025: electroCore to Participate in Upcoming Investor Conferences
  • 6.3.15 May 01, 2025: Boston Scientific Announces Upcoming Investor Conference Schedule
  • 6.3.16 Mar 26, 2025: NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
  • 6.3.17 Mar 03, 2025: NeuroPace to Present at the Leerink Partners Global Healthcare Conference
  • 6.3.18 Feb 28, 2025: SK Bioscience Wins Additional Varicella Vaccine Orders in Latin America
• 6.4 Legal And Regulatory
  • 6.4.1 Jan 15, 2026: Zynex : Update
  • 6.4.2 May 23, 2025: All Samples Analyzed From the 30 MG Dose Group in the Nex-22 Phase I Study
  • 6.4.3 Apr 10, 2025: Genflow Biosciences Launches New Ophthalmology Development Program Signs MTA with Leading Ophthalmology Company
• 6.5 Other Significant Developments
  • 6.5.1 Nov 24, 2025: NeuroPace Announces Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
  • 6.5.2 Nov 24, 2025: SetPoint Medical Receives CMS Transitional Pass-Through Payment Approval for SetPoint System
  • 6.5.3 Nov 20, 2025: Nexstim Receives NBS 6 System Order From New Research Customer
  • 6.5.4 Nov 17, 2025: Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study
  • 6.5.5 Nov 12, 2025: NeurAxis Announces Medical Policy Coverage Expansion in Michigan
  • 6.5.6 Nov 10, 2025: Hope Therapeutics, Inc. Announces First-in-Florida Initiation of One Day Depression Treatment
  • 6.5.7 Nov 04, 2025: BrainsWay Announces NIH Grant for Research on Accelerated Deep TMS for Alcohol Use Disorder
  • 6.5.8 Nov 04, 2025: Free Early Detection Alzheimer's Tests in Dearborn, MI
  • 6.5.9 Nov 03, 2025: Cefaly Achieves Milestone as Most Prescribed Neuromodulation Device by Veterans Health Administration
  • 6.5.10 Oct 24, 2025: Laser Procedure Offers Solutions For Epilepsy And Brain Tumors
  • 6.5.11 Oct 20, 2025: Spark Biomedical Receives NIH Grant to Investigate tAN Technology for Alcohol Withdrawal Symptoms
  • 6.5.12 Oct 13, 2025: Onward Medical Provides Q3 2025 Update on ARC-EX Adoption
  • 6.5.13 Oct 07, 2025: Nexstim Receives System Order From US Clinic
  • 6.5.14 Oct 06, 2025: Study Shows Cala TAPS Therapy Reduces Hand Tremor in Essential Tremor Patients by Modulating Brain Activity
  • 6.5.15 Oct 06, 2025: NeuroOne Reports 163% Growth in Preliminary Unaudited Product Revenue to $9.1 Million
  • 6.5.16 Oct 02, 2025: CLDN18.2 CaAR-T Cells Eliminate Pancreatic Cancer Cells
  • 6.5.17 Sep 18, 2025: Panaxium Research Signs Exclusive IP Agreement With University of Washington
  • 6.5.18 Sep 17, 2025: Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
  • 6.5.19 May 25, 2025: Biocon Biologics Receives MHRA, UK Approval for YESINTEK, Biosimilar Ustekinumab
  • 6.5.20 Apr 02, 2025: NeuroPace Announces Refocusing of Product Portfolio
• 6.6 Product News
  • 6.6.1 Jan 14, 2026: Integer to Showcase Innovations in Neuromodulation, Miniaturized Active Implantable Device Technology During NANS 2026 Annual Meeting
  • 6.6.2 Jan 08, 2026: Surf Therapeutics Announces Early Feasibility Study (EFS) To Advance Non-Invasive Approach to Neuromodulation for Rheumatoid Arthritis
  • 6.6.3 Nov 28, 2025: Yale-Trained Neuroscientist Introduces Panbrain Lume "Digital Sunshine" Device to Improve Sleep
  • 6.6.4 Nov 28, 2025: Mike Bako and RENPHO Showcase Health Technology on YourUpdateTV
  • 6.6.5 Nov 24, 2025: SetPoint Medical Receives CMS Transitional Pass-Through Payment Approval for SetPoint System
  • 6.6.6 Nov 20, 2025: Paradromics Receives FDA Approval for Connect-One Clinical Study with Connexus Brain-Computer Interface
  • 6.6.7 Nov 20, 2025: PhotoPharmics Exceeds Enrollment Goal with 350 Participants in Remote Phase 3 Clinical Trial for Parkinson's Disease
  • 6.6.8 Nov 20, 2025: Neuralink Rival Paradromics Cleared to Begin Brain-Implant Trial
  • 6.6.9 Nov 18, 2025: QuantalX Receives FDA De Novo Clearance for Delphi-MD
  • 6.6.10 Nov 17, 2025: BrainsWay Launches Clinical Trial of Deep TMS 360 System for Alcohol Use Disorder
  • 6.6.11 Nov 15, 2025: Evidence Builds for Disrupted Mitochondria as Cause of Parkinson's
  • 6.6.12 Nov 13, 2025: BrainsWay Receives FDA Clearance for Deep TMS as Adjunct Therapy for Major Depressive Disorder in Adolescents
  • 6.6.13 Nov 12, 2025: NeurAxis Announces Medical Policy Coverage Expansion in Michigan
  • 6.6.14 Nov 12, 2025: Theranica's Nerivio REN Wearable Demonstrates Long-Term Efficacy in Migraine Treatment
  • 6.6.15 Nov 10, 2025: URI Team Develops Tabletop Device to Study Long-Term Effects of Traumatic Brain Injury
  • 6.6.16 Nov 06, 2025: Synchron Secures $200 Million Series D Funding for Brain-Computer Interface Development
  • 6.6.17 Nov 06, 2025: PhotoPharmics Exceeds Enrollment Target with 350 Participants in Remote Clinical Trial
  • 6.6.18 Nov 06, 2025: NeuroCytonix Receives COFEPRIS Authorization for Neuro-Restorative Treatment in Mexico
  • 6.6.19 Nov 05, 2025: Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for Alzheimer's Treatment
  • 6.6.20 Nov 05, 2025: MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer's Patients
  • 6.6.21 Nov 03, 2025: Cefaly Achieves Milestone as Most Prescribed Neuromodulation Device by Veterans Health Administration
  • 6.6.22 Nov 03, 2025: NeuroSigma Publishes Study on Real-Time Effects of External Trigeminal Nerve Stimulation on Brain Activity
  • 6.6.23 Oct 31, 2025: European Investment Bank Supports German MedTech with €20 Million for PRECISIS
  • 6.6.24 Oct 30, 2025: Nexalin Technology Receives Regulatory Approval for Gen 2 SYNC Neurostimulation Device in Israel
  • 6.6.25 Oct 30, 2025: Siddiqui Performs World's First Robotic Microsurgical Intracranial Brain Surgery
  • 6.6.26 Oct 29, 2025: Incision-Free Brain Surgery Restores Smile for Parkinson's Patient
  • 6.6.27 Oct 29, 2025: FDA-Approved Focused Ultrasound Treatment for Essential Tremor Now Used for Parkinson's
  • 6.6.28 Oct 28, 2025: OHSU First In Nation To Use New Incisionless Surgery For Parkinson's Treatment
  • 6.6.29 Oct 24, 2025: NeurAxis Receives FDA Clearance for Pain Treatment in Functional Dyspepsia
  • 6.6.30 Oct 23, 2025: Miramont Wellness Centers Introduces New Device and Program for Treating Depression
  • 6.6.31 Oct 21, 2025: Nexalin's DIFS Neurostimulation Demonstrates Cognitive Improvements in Alzheimer's and Dementia
  • 6.6.32 Oct 20, 2025: Neupulse Partnership Introduces Innovative Wearable for Tourette Syndrome
  • 6.6.33 Oct 14, 2025: NeuroOne Expands Patent Portfolio With Recent USPTO and EPO Decisions
  • 6.6.34 Oct 13, 2025: Onward Medical Provides Q3 2025 Update on ARC-EX Adoption
  • 6.6.35 Oct 13, 2025: Zeta Surgical TMS Navigation System Receives FDA Clearance
  • 6.6.36 Oct 08, 2025: Nexalin Technology Reports Positive Clinical Results for Alzheimer's with Gen-2 SYNC Device
  • 6.6.37 Oct 07, 2025: Oxeia Biopharmaceuticals Recognized As Most Innovative Mild Traumatic Brain Injury Company for 2025
  • 6.6.38 Oct 06, 2025: Study Shows Cala TAPS Therapy Reduces Hand Tremor in Essential Tremor Patients by Modulating Brain Activity
  • 6.6.39 Oct 01, 2025: BalanceWear(R) for Multiple Sclerosis: Enhance Stability and Mobility
  • 6.6.40 Sep 30, 2025: Sequana Medical Features Alfapump System at 2025 Portal Intervention Symposium
  • 6.6.41 Sep 25, 2025: Nexalin Technology Issues U.S. Patent for HALO Clarity Device with DIFS Technology
  • 6.6.42 Sep 24, 2025: Eysz Announces Positive Results of NIH-Funded Study on Novel Absence Seizure Screening Tool
  • 6.6.43 Sep 23, 2025: FDA Clears Cionic Neural Sleeve 2 For Enhanced Mobility Care
  • 6.6.44 Sep 19, 2025: Medtronic Receives FDA Approval for Altaviva Device to Treat Urge Urinary Incontinence
  • 6.6.45 Sep 18, 2025: Panaxium Research Signs Exclusive IP Agreement With University of Washington
  • 6.6.46 Sep 17, 2025: Soft Bioelectronic Fiber Tracks Hundreds of Biological Events Simultaneously
  • 6.6.47 Sep 16, 2025: Non-Invasive Neuromodulation Boosts Physical Therapy
  • 6.6.48 Sep 15, 2025: Inbrain Neuroelectronics Collaborates to Enhance Graphene-Based Brain-Computer Interfaces
  • 6.6.49 Sep 10, 2025: Neurocare Group's Apollo TMS Therapy Devices Granted FDA Clearance for Treating Adolescent Depression
  • 6.6.50 Sep 08, 2025: Onward Medical Receives CE Mark for Arc-Ex, Enabling Commercial Launch in Europe
  • 6.6.51 Aug 20, 2025: Vivani Medical CEO Adam Mendelsohn To Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
  • 6.6.52 Jul 30, 2025: Neurotek Announces Debut of MOXO360
  • 6.6.53 May 28, 2025: Nyxoah to Present at the Jefferies Global Healthcare Conference
  • 6.6.54 Mar 03, 2025: KYOCERA to Showcase Ceramic Lab Analytic Technologies for Multilayer Direct Bonding, Ceramic Additive Manufacturing, and Sapphire Apertures at Pittcon 2025
  • 6.6.55 Feb 06, 2025: Electrocore Expands Intellectual Property Portfolio
  • 6.6.56 Feb 03, 2025: Integer to Showcase Leadership in Medical Device Innovation and Recent Acquisition of Precision Coating at MD&M West 2025
  • 6.6.57 Jan 28, 2025: Integer To Highlight Innovations in Neuromodulation, Next Generation of Miniaturized Active Implantable Devices During Nans 2025 Annual Meeting
• 6.7 Strategy And Business Planning
  • 6.7.1 Nov 13, 2025: Nexalin Technology Appoints Carmi Masha Technologies Ltd. As Exclusive Distributor In Israel
  • 6.7.2 Nov 12, 2025: NeurAxis Announces Medical Policy Coverage Expansion in Michigan
  • 6.7.3 Nov 06, 2025: Synchron Secures $200 Million Series D Funding for Brain-Computer Interface Development
  • 6.7.4 Oct 31, 2025: European Investment Bank Supports German MedTech with €20 Million for PRECISIS
  • 6.7.5 Oct 30, 2025: Nexalin Technology Receives Regulatory Approval for Gen 2 SYNC Neurostimulation Device in Israel
  • 6.7.6 Sep 18, 2025: Panaxium Research Signs Exclusive IP Agreement With University of Washington
  • 6.7.7 Sep 17, 2025: Vivani Medical Sets Record Date for Cortigent Spin-off
  • 6.7.8 Sep 15, 2025: Inbrain Neuroelectronics Collaborates to Enhance Graphene-Based Brain-Computer Interfaces
  • 6.7.9 Apr 24, 2025: Cirtec Medical Expands Costa Rica Operations to Support Increased Industry Demand
  • 6.7.10 Mar 13, 2025: Helius Medical Technologies Announces the Establishment of a Wholly Owned Brain Computer Interface ("Bci") Technology Private Subsidiary

7 Appendix

• 7.1 Research Methodology
  • 7.1.1 Coverage
  • 7.1.2 Secondary Research
  • 7.1.3 Primary Research
  • 7.1.4 Market Modeling and Forecasting
  • 7.1.5 Company Share Analysis
  • 7.1.6 Benchmarking
• 7.2 GlobalData Consulting
• 7.3 Contact Us
• 7.4 Disclaimer

List of Table

List of Tables

• Table 1: Neuromodulation Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
• Table 2: Implantable Neuromodulation Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
• Table 3: Neuromodulation Devices Market, United States, Volume (Units), 2018-2033
• Table 4: Implantable Neuromodulation Devices Market, United States, Volume (Units), 2018-2033
• Table 5: Neuromodulation Devices Market, United States, Average Price ($), 2018-2033
• Table 6: Neuromodulation Devices Market, United States, Company Share by Revenue ($m), 2025
• Table 7: Neuromodulation Devices Market Pipeline Products
• Table 8: Total Number of Primary Research Participants, Neurology Devices Market, by Country

List of Figure

List of Figures

• Figure 1: Neuromodulation Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
• Figure 2: Implantable Neuromodulation Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
• Figure 3: Neuromodulation Devices Market, United States, Volume (Units), 2018-2033
• Figure 4: Implantable Neuromodulation Devices Market, United States, Volume (Units), 2018-2033
• Figure 5: Neuromodulation Devices Market, United States, Company Share (%), 2025